Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration



Status:Completed
Conditions:Cardiology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - 85
Updated:2/7/2015
Start Date:November 2011
End Date:January 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing
Lucentis or avastin treatment.


Inclusion Criteria:

- Male or female age 18 to 85 with diabetes and hemoglobin A1C macular degeneration.

- Diabetic macular edema with average retinal thickness central subfield >/= 290um.

Exclusion Criteria:

- Macular atrophy/fibrosis.

- Ocular anti-VEGF treatment within 3 months.

- Treatment with topical or oral carbonic-anhydrase inhibitor within one month

- Laser photocoagulation within 3 months (diabetic cohort)
We found this trial at
1
site
Vitreo-Retinal Associates
Grand Rapids, Michigan 49525
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials